Next Article in Journal
In Vitro Exposure to Glucose Alters the Expression of Phosphorylated Proteins in Platelets
Next Article in Special Issue
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review
Previous Article in Journal
Small Molecule GSK-3 Inhibitors Safely Promote the Proliferation and Viability of Human Dental Pulp Stem Cells—In Vitro
Previous Article in Special Issue
Protective Effect of Red Rice Extract Rich in Proanthocyanidins in a Murine Colitis Model
 
 
Systematic Review
Peer-Review Record

Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review

Biomedicines 2023, 11(2), 544; https://doi.org/10.3390/biomedicines11020544
by Monica State 1,2 and Lucian Negreanu 1,3,*
Reviewer 1: Anonymous
Reviewer 2:
Biomedicines 2023, 11(2), 544; https://doi.org/10.3390/biomedicines11020544
Submission received: 30 January 2023 / Revised: 10 February 2023 / Accepted: 10 February 2023 / Published: 13 February 2023
(This article belongs to the Special Issue Novel Therapeutic Approaches in Inflammatory Bowel Diseases 3.0)

Round 1

Reviewer 1 Report

-       - Use oxford comma

 

-        - PROSPERO ID 395550 in not present among protocols in evaluation

 

-        - “A retrospective analysis of 15 patients using either VEDO+IFX, USTE+IFX or VEDO+USTE identified frequent infections requiring antibiotics, the need for surgical intervention and hospitalization in a 24-month follow-up period.”

 

Other data a more encouraging (cite: “Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scand J Gastroenterol. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159. Epub 2019 Apr 4. PMID: 30945576.”)

 

-    -    Add the limitations of your paper

 

-      -  Try to propose a definition of assessment of a lack/loss of response that could be used in all RCT and clinical practice

Author Response

Dear reviewer,

On behalf of all the authors, I would like to thank you for you comments and suggestions. We addressed all the issues raised as follows:

  • We added the registration record for PROSPERO. Our protocol is not yet registered, but is being assessed by the editorial team (attached below)
  • The citation you recommended was included in the combination therapy section
  • We added a paragraph for limitations
  • We proposed a definition of assessment of loss of response

The authors,

Reviewer 2 Report

In the present systematic review State et al summarized the main definitions of therapy failure for monoclonal antibodies in IBD, as well as definition of clinical/endoscopic remission and strategies for therapy optimization, showing a relevant heterogeneity.

This is an excellent review which clearly shows definitions used in clinical practice and trials. However, before starting therapy optimization, it would be better to discriminate between primary/secondary non response or loss of response. Therefore definitions of such situations should be added in the text (the definitions in page 9 lines 156-159 are quite vague, and a timing should be reported).

As shown in tables 1-2, heterogeneity exists only for CD. Please underline this.

Author Response

 

Dear reviewer,

On behalf of all the authors, I would like to thank you for you comments and suggestions. We addressed all the issues raised as follows:

  • We expanded the definitions of LOR and added timing considerations recommened in current guidelines
  • We underlined the limited heterogencity to CD of LOR definition

 

The authors,

 

Back to TopTop